Global Synthetic Biology Market Research Report 2016satPRnews (press release)The study scope includes core synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, production systems), enabling… Continue reading
DailyCommerceNewsGlobal Synthetic Biology Market Research Report 2016MilTechThe study scope includes core synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, production systems), enabling … Continue reading
|
Synthetic Biology Market to Grow Rapidly Worldwide till 2024 Owing …
MENAFN.COM (MENAFN Editorial) Synthetic Biology Market Size, Application Analysis, Share, Growth, Trends, Regional Outlook, Competitive Strategies and Forecasts, 2016 … Global Synthetic Biology Market Research Report 2016 – satPRnewssatPRnews (press release) Synthetic Biology Market Size, Analysis, and Forecast Report 2016 …Medgadget (blog) |
Technology Networks |
World Vaccine & Immunotherapy Congress West Coast
Technology Networks Following a hugely successful World Vaccine Congress in Washington in April we’re bringing the World Vaccine & Immunotherapy Congress to San Diego from Nov 30 – Dec 1 where we’ll be integrating the technologies revolutionising immunotherapy and its … |
San Francisco Chronicle |
10-year, $1B life sciences plan bears fruit in Massachusetts
San Francisco Chronicle In this Monday, Aug. 14, 2017 photo, researcher Leonard Zon, founder and director of the Stem Cell Program at Boston Children’s Hospital, stands for a photograph among rows of containers holding about 300,00 zebrafish in a lab at the hospital, in Boston. |
MIT Technology Review |
Doctors Plan Bold Test of Gene Therapy on Boys with Muscular Dystrophy
MIT Technology Review Using mini-genes inspired by the man’s genetic defect, three U.S. teams say they are ready to try to treat Duchenne with gene therapy. The first study could begin as soon as next month at Nationwide Children’s Hospital in Columbus, Ohio, with the … |
|
Immunotherapy drug shows favorable safety profile in patients with advanced small cell lung cancer
News-Medical.net The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an … |